Top 10 of Basic Science

Moderator: Georg Behrens, Germany

Charlotte Charpentier, France
Agnès Libois, Belgium
<table>
<thead>
<tr>
<th>1st Author</th>
<th>Title of “TOP 8 ARTICLES“</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lederman MM</td>
<td>A cure for HIV infection: &quot;Not in My Lifetime&quot; or &quot;Just Around the Corner&quot;?</td>
<td>Pathog Immun (1), Spring 2016</td>
</tr>
<tr>
<td>Barouch DH</td>
<td>Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys</td>
<td>Cell (165), April 2016</td>
</tr>
<tr>
<td>Lorenzo-Redondo R</td>
<td>Persistent HIV-1 replication maintains the tissue reservoir during therapy</td>
<td>Nature (530), February 2016</td>
</tr>
<tr>
<td>Gautam R</td>
<td>A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges</td>
<td>Nature (533), May 2016</td>
</tr>
<tr>
<td>Scheid JF</td>
<td>HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption</td>
<td>Nature (535), July 2016</td>
</tr>
<tr>
<td>Byrareddy SN</td>
<td>Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy</td>
<td>Science (354), October 2016</td>
</tr>
<tr>
<td>Borducchi EN</td>
<td>Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys</td>
<td>Nature, November 2016</td>
</tr>
</tbody>
</table>
A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”?

AUTHORS
Michael M. Lederman¹, Paula M. Cannon², Judith S. Currier³, Carl H. June⁴, Hans-Peter Kiem⁵, Daniel R. Kuritzkes⁶, Sharon R. Lewin⁷, David M. Margolis⁸, Joseph M. McCune⁹, John W. Mellors¹⁰, Timothy W. Schacker¹¹, Rafick P. Sekaly¹¹, Pablo Tebas¹⁴, Bruce D. Walker¹², Daniel C. Douek¹³
• Michael Lederman and Daniel Douek (editors of *Pathogens and Immunity*) ask whether curing HIV is a realistic, scalable objective: overview perspective
Complete HIV eradication will not be simple and may not even be possible

- **Virus quiescence** in host cell genomes → Reservoir, infected cells not easily visible to host defenses.
- HIV-specific CD8: frequency↓ with ↓ VL with ART and « exhausted » phenotype
- Infected cells broadly distributed in numerous tissues, including sites relatively inaccessible to host defenses or treatment strategies
- “**Functional cure**”: broadly defined as a state in which ART may be withdrawn without subsequent virus recrudescence

The “Berlin patient”: only one person cured

Elite controllers
  – Sustained low levels of plasma viremia in the absence of ART
  – But inflammation and coagulation > in ART-controlled HIV+
  – Progressive CD4 decline occurs
    • ATCG trial ongoing in elite controllers: effect of ART on inflammation and CD4

Is the goal of achieving functional cure as defined by elite controller status good enough?

• Current ART: durable control of HIV with once daily well-tolerated single pill
• With early start treatment, sustain normal CD4 and predicted survival similar to that of uninfected persons

➡️ The bar for a cure strategy is high!

Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys

Dan H. Barouch, Khader Ghneim, William J. Bosche, Yuan Li, Brian Berkemeier, Michael Hull, Sanghamitra Bhattacharyya, Mark Cameron, Jinya Liu, Kaitlin Smith, Erica Borducchi, Crystal Cabral, Lauren Peter, Amanda Brinkman, Mayuri Shetty, Hualin Li, Courtney Gittens, Chantelle Baker, Wendeline Wagner, Mark G. Lewis, Arnaud Colantonio, Hyung-Joo Kang, Wenjun Li, Jeffrey D. Lifson, Michael Piatak Jr.8, Rafick-Pierre Sekaly
• **Background**
  – The earliest events following mucosal HIV-1 infection, prior to measurable viremia, remain poorly understood

• **Objectives**
  – Evaluate the kinetics of virus dissemination to distal tissues
  – Evaluate the initial innate and adaptive host immune responses following intra-vaginal SIV infection of rhesus monkeys

Barouch DH et al., *Cell*, 2016
• **Material & method**
  - 44 female rhesus monkeys (*Macaca mulatta)*
  - Infection with SIVmac251 (5 x 10⁴ TCID₅₀) by the intravaginal route
  - Necropsies on days 0, 1, 3, 7 or 10 following infection (multiple samples of 23-37 tissues)
  - SIV RNA and DNA quantification (real time PCR)
  - Transcriptomic analysis: Illumina© platform
Viral RNA in tissues \((\log_{10}\text{SIV RNA c}/10^6 \text{ cells})\)

- **Day 1**
- **Day 3**
- **Day 7**

- Rapid kinetics of virus dissemination from the site of inoculation to distal tissues

Barouch DH et al., Cell, 2016
Tissu viral DNA ($\log_{10}$ SIV DNA c/10^8 cells)

Barouch DH et al., Cell, 2016
**Correlation analysis between NLRX1 expression and viral RNA levels in GALT**

- NLRX1 is a negative regulator of the inflammasome pathway that inhibits expression of antiviral ISGs, IRF7, RIG-I, and TLRs
- NLRX1 suppresses antiviral restriction factors
  - Innate immunity

**CD8+ T lymphocyte responses in tissues are correlated inversely with TGIF1 expression**

- Triggering of the TGF-β pathway was an early event
- Inverse correlation with the magnitude of CD4+ and CD8+ T responses in GALT
  - Adaptive immunity

Barouch DH *et al.*, *Cell*, 2016
Conclusions

- The virus triggers initial proinflammatory host responses that
  - downregulate innate antiviral immunity
  - inhibit adaptive cellular immunity
  - facilitate viral replication at sites of early distal dissemination

Barouch DH et al., Cell, 2016
Persistent HIV-1 replication maintains the tissue reservoir during therapy

Ramon Lorenzo-Redondo¹*, Helen R. Fryer²*, Trevor Bedford³, Eun-Young Kim¹, John Archer⁴, Sergei L. Kosakovsky Pond⁵†, Yoon-Seok Chung⁶, Sudhir Penugonda¹, Jeffrey G. Chipman⁷, Courtney V. Fletcher⁸, Timothy W. Schacker⁹, Michael H. Malim¹⁰, Andrew Rambaut¹¹, Ashley T. Haase¹², Angela R. McLean² & Steven M. Wolinsky¹

February 2016 | Vol 530 | Nature | 51
**Background:** low-level viremia can result from

<table>
<thead>
<tr>
<th>Reactivation of a small proportion of latently infected CD4+ T cells</th>
<th>Low levels of ongoing replication</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No replication</td>
<td>- Replication</td>
</tr>
<tr>
<td>- No mutation and no viral genetic divergence over time</td>
<td>- Introduction of mutations → genetic evolution</td>
</tr>
<tr>
<td></td>
<td>- However, <strong>NO</strong> emergence of resistance mutations</td>
</tr>
</tbody>
</table>

**Objective:** to assess whether cART fully suppresses viral replication in lymphoid tissue reservoirs

**Material & method**
- 3 patients at 3 different time points (baseline, M3 and M6 after ARV initiation):
  - 2 were in first-line and the remaining was ARV-experienced but ARV were stopped since 1 year
- Sampling of plasma, PBMC and inguinal lymph nodes
- Ultra-deep sequencing

Time-structured phyloanatomic history of sequences in lymph nodes and blood (gag region)

Virus evolution and trafficking between tissue compartments continues in patients with undetectable levels of virus in the plasma compartment

Hypothetical fitness landscape, which portrays the relationship between the fitness of each strain and the evolutionary adaptation across a range of drug concentrations.

These findings showed a continued virus production from infected cells in lymphoid tissue sanctuary sites, where drug concentrations are not fully suppressive, that can continue to replenish the viral reservoir and traffic to blood or lymphoid tissue.

This viral production does not inevitably develop resistance to ARV because the lower concentration of drugs in the sanctuary sites (not sufficient to confer a competitive advantage upon drug-resistant strains).

These findings explain the failure of ARV intensification to fully suppress de novo infections.

Achieving optimal cellular PK and spatial distribution of ARV in lymphoid tissue to fully suppress viral replication and preserve immune function would be a prerequisite to the elimination of the viral reservoir and ultimately a step towards a cure for HIV-1 infection.
A single injection of anti–HIV–1 antibodies protects against repeated SHIV challenges

Rajeev Gautam1*, Yoshiaki Nishimura1*, Amarendra Pegu2, Martha C. Nason3, Florian Klein4,5,6, Anna Gazumyan4, Jovana Golijanin4, Alicia Buckler-White1, Reza Sadjadpour1, Keyun Wang2, Zachary Mankoff2, Stephen D. Schmidt2, Jeffrey D. Lifson7, John R. Mascola2, Michel C. Nussenzweig4,8 & Malcolm A. Martin1

5 MAY 2016 | VOL 533 | NATURE | 105

- **Objective:** to explore the possibility that a single administration of a potent neutralizing anti-HIV monoclonal antibodies (MAb), in the setting of repeated low-dose SHIV challenges, might protect for extended periods of time, thereby providing a proof of concept for periodic administration of MAb as an alternative to HIV-1 vaccination
Material & method

- Individual MAbs (20 mg kg$^{-1}$) were administered a single time intravenously to four cohorts of six macaques
  - **VRC01**: targets the gp120 CD4 binding site
  - **3BNC117**: targets the gp120 CD4 binding site
  - **10-1074**: dependent on the presence of HIV-1 gp120 N332 glycan, located immediately downstream of the V3 loop
  - **VRC01-LS**: introduction of two amino-acid mutations (M428L and N434S, referred to as ‘LS’) into Fc domain of VRC01 ➔ improvement of the PK profile of VRC01 with an increased half-life in both plasma and tissues

- Starting 1 week later, each group was challenged weekly by the intrarectal route with ten TCID$_{50}$ of SHIV$_{AD8-EO}$, in the absence of antibody treatment (study design in order to simulate low-dose mucosal transmission in humans)

HIV MAbs delay virus acquisition after repeated low-dose intrarectal SHIV$_{AD8-EO}$ challenges (Figure 1)

Compared with control animals, which required two to six challenges (median, n = 3) for infection, a single broadly neutralizing antibody infusion prevented virus acquisition for up to 23 weekly challenges.

The introduction of a mutation that extends antibody half-life of VRC01 increased median protection from 8 to 14.5 weeks.

The duration of protection was directly related to antibody potency and half-life.

In conclusion, this is a proof of concept that a single administration of potent anti-HIV-1-neutralizing MAbs to naive macaques was protective against repeated low-dose SHIV infection for several months.

Administered to populations at high risk of HIV-1 transmission, such an immunoprophylaxis regimen could have a major impact on virus transmission.

LETTER

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Johannes F. Scheid1,2*, Joshua A. Horwitz1*, Yotam Bar-On1, Edward F. Kreider3, Ching-Lan Lu1, Julio C. C. Lorenzi1, Anna Feldmann4, Malte Braunschweig1, Lilian Nogueira1, Thiago Oliveira1, Irina Shimeliovich1, Roshni Patel1, Leah Burke5, Yehuda Z. Cohen1, Sonya Hadrigan1, Allison Settler1, Maggi Witmer-Pack1, Anthony P. West Jr6, Boris Juelg7, Tibor Keler8, Thomas Hawthorne8, Barry Zingman9, Roy M. Gulick5, Nico Pfeifer4, Gerald H. Learn3, Michael S. Seaman10, Pamela J. Bjorkman6, Florian Klein1,11,12, Sarah J. Schlesinger1, Bruce D. Walker7,13, Beatrice H. Hahn3, Michel C. Nussenzweig1,14 & Marina Caskey1

doi:10.1038/nature18929
Background

• Animal models: bNAbs show potent prophylactic activity, suppress established viraemia, and delay viral rebound during analytical treatment interruption (ATI)

• In humans: a phase I clinical trial showed that 3BNC117 is
  – Safe, well tolerated
  – A single infusion of 3BNC117 ↓ VL by 1.5 log10 cp/ml, with durable activity for 4 weeks

Method

- Phase IIa open label clinical trial
- 3BNC117: broad and potent neutralizing antibody against the CD4 binding site of the HIV-1 Env protein
- 63 individuals screened for sensitivity to 3BNC117: 11% resistant, 65% sensitive
- 13 patients (VL <20 cp/ml >12 months, CD4>500/mm³, 3BNC117-sensitive). 2 groups with different schedule of infusions
- Analytical treatment interruption (ATI) 2 days after the first 3BNC117 infusion
- ART reinitiated and infusions stopped after 2 consecutive VL>200 cp/ml

Antibodies Bound to the Four Sites of Vulnerability

- V1–V2 Loop
  - PGT121-PGT123
  - 10-1074

- V3 Loop
  - PGDM1400

- CD4-binding site
  - VRC01-03
  - 3BNC117

- gp120
- gp41

- Envelope spike

HIV-1
Results (1)

- Well tolerated, safe (no acute retroviral syndrome during rebound, VL<20 cp/ml within 2–7 weeks after restarting ART)
- Half-life of 3BNC117 during ATI: 2-3 weeks

- Average time to rebound 8.4 weeks compared with 2.6 weeks for matched historical non-infused control individuals ($P < 0.00001$)
- 6/13 (46%) individuals remained suppressed until at least 9 weeks after ATI
Results (2)

- A majority (8/13) of participants had rebound viruses more resistant to 3BNC117
- Rebound viruses arise predominantly from a single provirus (5/8 individuals)
- Time to rebound did not correlate with the amount of viral DNA in PBMCs (but this is a poor measure of the reservoir, since most integrated proviruses in patients on ART are defective)

Conclusion

• Administration of bNAb 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during analytical treatment interruption in humans

• Immunotherapy will probably require combinations of bNAbs that target different sites to increase the frequency of individuals that remain suppressed by antibody during ATI

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Aim & method

- VRC01: bNAb that targets the CD4-binding site
- To determine whether administration of VRC01, can safely prevent or delay plasma viral rebound after the discontinuation of ART in humans
- 2 open-label trials phase I (ACTG A5340 and NIH15-I-0140)
- Study participants were not prescreened for sensitivity of the virus to neutralization by VRC01
Results

- 24 participants (22 M-2F)
- Safe
- Viral rebound occurred despite high plasma VRC01 concentrations
- Median time to rebound was 4 weeks and 5.6 weeks according to the trial
- Compared to historical controls, participants more likely to have viral suppression at week 4 but the difference was not significant at week 8
  ➔ Slightly delayed viral rebound
Results

• Baseline resistance to VRC01 common
• Nearly all participants who had viral rebound early with high concentrations of plasma VRC01 had rebound with resistant virus

⇒ Considerable challenge in the use of bNAbs as therapeutic agents

Other tested bNAbs appeared to have less prevalent archived resistance
HIV-1 THERAPY

Sustained virologic control in SIV\(^+\) macaques after antiretroviral and \(\alpha_4\beta_7\) antibody therapy

Siddappa N. Byrareddy,\(^{1,}\dagger\) James Arthos,\(^{2}\) Claudia Cicala,\(^{2}\) Francois Villinger,\(^{1,}\ddagger\) Kristina T. Ortiz,\(^1\) Dawn Little,\(^1\) Neil Sidell,\(^4\) Maureen A. Kane,\(^5\) Jianshi Yu,\(^5\) Jace W. Jones,\(^5\) Philip J. Santangelo,\(^6\) Chiara Zurla,\(^6\) Lyle R. McKinnon,\(^7,\S\) Kelly B. Arnold,\(^8\) Caroline E. Woody,\(^8\) Lutz Walter,\(^9\) Christian Roos,\(^9\) Angela Noll,\(^9\) Donald Van Ryk,\(^2\) Katija Jelicic,\(^2\) Raffaello Cimbro,\(^10\) Sanjeev Gumber,\(^3\) Michelle D. Reid,\(^1\) Volkan Aksay,\(^1\) Praveen K. Amancha,\(^3\) Ann E. Mayne,\(^1\) Tristram G. Parslow,\(^1\) Anthony S. Fauci,\(^2\) Aftab A. Ansari\(^3\)|

Background

• High levels of viral replication in gastrointestinal tissues (GITs) during acute infection
  ➔ Severe depletion of local CD4+ T cells
  ➔ Damage to the gut epithelium
  ➔ Rapid formation of persistent viral reservoirs

• **Hypothesis**: preventing HIV susceptible cells from accessing GITs might reduce damage to the gut and the mucosal immune system?

• CD4+ T use to traffic into GITs involves an interaction between integrin α4β7, expressed on CD4+ T, with a mucosal vascular adhesion molecule 1 (MAdCAM-1), expressed within GITs

Recombinant rhesus monoclonal antibody against α4β7 (α4β7 mAb) that blocks α4β7 binding to MAdCAM → Stop susceptible immune cells from entering intestinal tissues

Antibody similar to vedolizumab (approved for IBD treatment)

Method

• 18 SIV-infected RMs
  – ART start 5 weeks post-infection (phase II) for 3 months
  – + 8 infusions of α4β7 mAb (n=11) or IgG (control group) (week 9-18)
  – ART stop + α4β7mAb–IgG 4 weeks

• 3/11 α4β7 mAb–treated animals developed antibodies against the α4β7 mAb \( \Rightarrow \) excluded

Combining $\alpha_4\beta_7$ mAb therapy with short term ART promoted persistent systemic and mucosal virologic control following discontinuation of all therapy.

Results

• In the α4β7-treated monkeys (blue), gradual restoration of CD4+ T cells
• CD4+ T cell subsets: apparent recovery of T central memory (CM) and T Effector Memory cells

• Immuno-PET–CT analysis at weeks 50 confirms preservation of CD4+
Conclusion

• Combining ART with α4β7 mAb promoted prolonged virologic control and the restoration of CD4+ T cells.

• Control persisted long after α4β7mAb treatment was terminated

• *A pilot clinical trial, testing the safety of vedolizumab and its effect on HIV in human, has begun at NIAID*
LETTER
doi:10.1038/nature20583

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV–Infected Rhesus Monkeys

Erica N. Borducchi, Crystal Cabral, Kathryn E. Stephenson, Jinyan Liu, Peter Abbink, David Ng’ang’a, Joseph P. Nkolola, Amanda L. Brinkman, Lauren Peter, Benjamin C. Lee, Jessica Jimenez, David Jetton, Jade Mondesir, Shanell Mojta, Abishek Chandrashekar, Katherine Molloy, Gilit Alter, Jeff M. Gerold, Alison L. Hill, Mark G. Lewis, Maria G. Pau, Hanneke Schuitemaker, Joseph Hesselgesser, Romas Geleziunas, Jerome H. Kim, Merlin L. Robb, Nelson L. Michael and Dan H. Barouch
Background and aim

• Little evidence exists that the viral reservoir can be sufficiently targeted to improve virologic control following discontinuation of ART
• Is a therapeutic vaccine will be able to induce cellular immune responses with sufficient potency and breadth to control viral rebound following ART discontinuation?
• TLR7 (toll-like receptor) triggering: activate dendritic cells and lymphocytes and lead to innate immune activation

• **Aim**: evaluation of Ad26/MVA therapeutic vaccination and TLR7 agonist administration in ART suppressed, SIV-infected rhesus monkeys

Method

• 36 monkeys, ART at 7 days post-infection
• Interventions after 24 weeks of suppressive ART
• 4 groups
  – (1) Ad26/MVA vaccines alone
  – (2) Ad26/MVA vaccines + TLR7 agonist GS-986
  – (3) TLR7 agonist GS-986 alone
  – (4) sham (control)
Results

• Immunogenicity of the Ad26/MVA vaccine
  – >100-fold ↑ in the magnitude of Gag-, Pol-, Env- specific cellular immune responses (compared with prevaccination responses)
  – Expanded cellular immune breadth by 10x → induction of responses to a large number of epitopes that were not detectable before vaccination
  – Modest humoral immune responses

Ad26/MVA vaccine: reductions of viral DNA to undetectable levels in the majority of animals by week 70 in lymph nodes and PBMC
→ Suggest ↓ CD4 infected

Stop ART at w72

- 3/9 animals in the combined group: virologic control to undetectable levels in the absence of ART
- Viral DNA in lymph nodes and PBMC correlated poorly with virologic control following ART discontinuation and time to viral rebound (P=0.03) → viral DNA assays are not sufficiently sensitive to predict functional cure

Vaccine+ TLR7: ↓ viral set-point 1.7 log and delay of viral rebound 2.5x

Conclusion

• The combination of Ad26/MVA vaccination and TLR7 stimulation
  – ↓ viral DNA in lymph nodes and peripheral blood
  – Improved virologic control and delayed viral rebound following ART discontinuation in SIV-infected RM that initiated ART during acute infection

• Potential of therapeutic vaccination with innate immune stimulation as a HIV-1 functional cure strategy